ADMA

Over the past six months, ADMA Biologics' stock was impacted by a short seller report from Culper Research in March 2026, alleging 'channel stuffing' and an undisclosed related party distributor, which led to significant stock price declines and subsequent class action lawsuits. ADMA refuted these allegations, asserting real demand for ASCENIV and industry-standard distributor stocking. In May 2026, the company received FDA approval to expand ASCENIV's label to include pediatric patients. Earnings reports for Q1 and Q2 2026 were released in May and August, respectively, with Q2 showing total revenue of $124.4 million (2% increase year-over-year) and ASCENIV revenue of $102.9 million (24% increase year-over-year), alongside a GAAP Net Income increase of 11%. The stock has experienced volatility, with a 52-week range between $7.21 and $20.46, and as of October 9, 2026, was around $10.36, showing recent gains but a yearly decrease.